• Novo Nordisk has entered into exclusive negotiations with BIO JAG, main shareholder of BIOCORP, with a view to purchasing its entire stake in BIOCORP, representing 45.3% of the share capital and 62.19% of the theoretical voting rights of BIOCORP (the “Control Block”), at a price of 35.00 euros per share.
• Certain minority shareholders, representing 19.0% of the share capital and 13.07% of the theoretical voting rights of BIOCORP, have undertaken to transfer their shares to Novo Nordisk following the acquisition by Novo Nordisk of the Control Block .
• The contemplated transaction would be followed by the filing by Novo Nordisk on a mandatory basis of a draft simplified takeover bid (OPA) relating to the balance of securities issued by BIOCORP in circulation and, if the legal conditions are met at the outcome of the offer, a squeeze-out procedure and the delisting of BIOCORP from Euronext Growth.
Bagsværd (Denmark), Issoire (France), June 5, 2023 at 7:00 a.m. CEST – Novo Nordisk A/S and BIOCORP Production SA announced today that they have entered into exclusive negotiations with a view to the acquisition by Novo Nordisk A/S of a control block in the capital of BIOCORP, which would be followed by the filing by Novo Nordisk on a mandatory basis of a simplified takeover bid (OPA) relating to the balance of the shares issued by BIOCORP at a price of 35.00 euros per share paid in cash, valuing 100% of the capital of BIOCORP at approximately 154 million euros.